Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
CNY 4.11
(2.49%)
CNY 4.11
(2.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 231.86 Million CNY | 13.32% |
| 2022 | 204.6 Million CNY | 168.91% |
| 2021 | -296.91 Million CNY | -241.81% |
| 2020 | 209.36 Million CNY | -28.5% |
| 2019 | 292.82 Million CNY | 181.35% |
| 2018 | -359.97 Million CNY | -226.39% |
| 2017 | 284.81 Million CNY | 28.32% |
| 2016 | 221.95 Million CNY | 242.0% |
| 2015 | 64.89 Million CNY | 41.99% |
| 2014 | 45.7 Million CNY | 19.13% |
| 2013 | 38.36 Million CNY | -56.65% |
| 2012 | 88.5 Million CNY | -7.07% |
| 2011 | 95.23 Million CNY | -22.66% |
| 2010 | 123.13 Million CNY | 35.81% |
| 2009 | 90.67 Million CNY | 98.41% |
| 2008 | 45.69 Million CNY | 751.81% |
| 2007 | 5.36 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 93.97 Million CNY | -23.28% |
| 2024 Q3 | 85.12 Million CNY | -9.42% |
| 2024 Q1 | 122.5 Million CNY | 713.35% |
| 2023 Q3 | 90.95 Million CNY | 21.49% |
| 2023 Q1 | 86.02 Million CNY | 25.45% |
| 2023 FY | 231.86 Million CNY | 13.32% |
| 2023 Q4 | -19.97 Million CNY | -121.96% |
| 2023 Q2 | 74.86 Million CNY | -12.97% |
| 2022 Q1 | 37.26 Million CNY | 107.84% |
| 2022 Q4 | 68.57 Million CNY | 42.22% |
| 2022 Q2 | 50.55 Million CNY | 35.68% |
| 2022 FY | 204.6 Million CNY | 168.91% |
| 2022 Q3 | 48.21 Million CNY | -4.63% |
| 2021 Q1 | 61.53 Million CNY | 343.45% |
| 2021 Q3 | 71.68 Million CNY | 58.51% |
| 2021 Q4 | -475.34 Million CNY | -763.12% |
| 2021 FY | -296.91 Million CNY | -241.81% |
| 2021 Q2 | 45.22 Million CNY | -26.5% |
| 2020 Q4 | 13.87 Million CNY | -78.03% |
| 2020 Q3 | 63.16 Million CNY | -1.19% |
| 2020 Q2 | 63.92 Million CNY | -6.53% |
| 2020 Q1 | 68.39 Million CNY | 1.74% |
| 2020 FY | 209.36 Million CNY | -28.5% |
| 2019 FY | 292.82 Million CNY | 181.35% |
| 2019 Q4 | 67.22 Million CNY | -7.64% |
| 2019 Q3 | 72.78 Million CNY | -7.53% |
| 2019 Q2 | 78.71 Million CNY | 6.23% |
| 2019 Q1 | 74.09 Million CNY | 112.58% |
| 2018 Q3 | 56.21 Million CNY | -33.12% |
| 2018 FY | -359.97 Million CNY | -226.39% |
| 2018 Q1 | 88.71 Million CNY | 86.66% |
| 2018 Q2 | 84.05 Million CNY | -5.25% |
| 2018 Q4 | -588.96 Million CNY | -1147.73% |
| 2017 FY | 284.81 Million CNY | 28.32% |
| 2017 Q2 | 91.43 Million CNY | 1.52% |
| 2017 Q4 | 47.52 Million CNY | -14.82% |
| 2017 Q1 | 90.05 Million CNY | 36.84% |
| 2017 Q3 | 55.79 Million CNY | -38.97% |
| 2016 Q3 | 72.34 Million CNY | 35.82% |
| 2016 FY | 221.95 Million CNY | 242.0% |
| 2016 Q4 | 65.81 Million CNY | -9.03% |
| 2016 Q2 | 53.26 Million CNY | 74.39% |
| 2016 Q1 | 30.54 Million CNY | 110.24% |
| 2015 Q1 | 9.14 Million CNY | 47.53% |
| 2015 Q3 | 23.01 Million CNY | 26.39% |
| 2015 FY | 64.89 Million CNY | 41.99% |
| 2015 Q4 | 14.52 Million CNY | -36.88% |
| 2015 Q2 | 18.21 Million CNY | 99.15% |
| 2014 Q4 | 6.19 Million CNY | -2.78% |
| 2014 FY | 45.7 Million CNY | 19.13% |
| 2014 Q1 | 16.42 Million CNY | 60.96% |
| 2014 Q2 | 16.71 Million CNY | 1.77% |
| 2014 Q3 | 6.37 Million CNY | -61.85% |
| 2013 Q4 | 10.2 Million CNY | 67.85% |
| 2013 FY | 38.36 Million CNY | -56.65% |
| 2013 Q1 | 15.7 Million CNY | 36.99% |
| 2013 Q2 | 6.38 Million CNY | -59.32% |
| 2013 Q3 | 6.07 Million CNY | -4.84% |
| 2012 FY | 88.5 Million CNY | -7.07% |
| 2012 Q3 | 22.31 Million CNY | -20.77% |
| 2012 Q1 | 26.55 Million CNY | 149.34% |
| 2012 Q4 | 11.46 Million CNY | -48.65% |
| 2012 Q2 | 28.16 Million CNY | 6.08% |
| 2011 Q3 | 16.6 Million CNY | -47.83% |
| 2011 Q4 | 10.65 Million CNY | -35.87% |
| 2011 Q2 | 31.83 Million CNY | -11.94% |
| 2011 FY | 95.23 Million CNY | -22.66% |
| 2011 Q1 | 36.14 Million CNY | 19.88% |
| 2010 Q2 | 30.58 Million CNY | -4.27% |
| 2010 Q1 | 31.95 Million CNY | 0.0% |
| 2010 Q4 | 30.15 Million CNY | -0.97% |
| 2010 Q3 | 30.44 Million CNY | -0.46% |
| 2010 FY | 123.13 Million CNY | 35.81% |
| 2009 FY | 90.67 Million CNY | 98.41% |
| 2008 FY | 45.69 Million CNY | 751.81% |
| 2007 FY | 5.36 Million CNY | 0.0% |